Expensify's P/S ratio is not in line with the industry median due to its underwhelming revenue outlook. Shareholders accept the low P/S, conceding future revenue probably won't surprise positively. A change of fortune is needed for a higher P/S.
Expensify's low P/S ratio, while seemingly attractive, mirrors its poor revenue performance and the anticipation of no improvement. Without a major shift, a significant stock price rise is doubtful. The low P/S ratio indicates no expected future revenue surprises.
The confident insider purchases in Expensify, even at a higher cost, signal belief in the company's future. Substantial insider ownership suggests alignment with shareholders.
Analysts are increasingly pessimistic about Expensify's future due to a significant cut in revenue estimates. This downgrade could potentially drive investors to sell their holdings, negatively impacting the company's future valuation. Market caution around Expensify may increase as a result.
Upgrades •$ボルグワーナー(BWA.US)$: Deutsche Bank Upgrades to Buy from Hold - PT $48 (from $43) •$エクスペンシファイ(EXFY.US)$: BofA Securities Upgrades to Buy from Neutral - PT $25 (from $20) •$グラブ・ホールディングス(GRAB.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $3 •$フーリハン・ローキー(HLI.US)$: Morgan Stanley Upgrades to Equalweight from Underweight - PT $82 (from $95) •$JPモルガン・チェース(JPM.US)$: Berenberg Upgrades to Hold from Sell - PT ...
$トーム(TRMD.US)$ - Stock breaking out and moving higher. Looking to add above $13 $エクスペンシファイ(EXFY.US)$ - stock breaking out after it reported earnings recently. Co announced a 50M buyback. Adding above $21.5 $JEクリーンテック・ホールディングズ(JCSE.US)$ - Recent IPO. moving higher after hitting bottom. Stocking having multiple green day recently. Watching next key resistance at $14.50 $H&Rブロック(HRB.US)$ - Stock breaking out on the recent earnings report. Needs to br...
Gainers: •$クロビス・オンコロジー(CLVS.US)$+40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial) •$デア・バイオサイエンス(DARE.US)$+13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO) •$クーラー・テクノロジー・グループ(KULR.US)$+9.5% (secured a battery sa...
エクスペンシファイに関するコメント
コラムToday's pre-market stock movers: RKLB, ILMN, TOST, BABA and more
In reaction to earnings/guidance:
• $ペイオニア・グローバル(PAYO.US)$ +19.4%,$トースト(TOST.US)$ +13.1%,$PDFソリューション(PDFS.US)$ +7.7%,$ホイールズ・アップ・エクスペリエンス(UP.US)$ +7.1%,$リーガルズーム(LZ.US)$ +6.5%,$ジョビー・アビエーション(JOBY.US)$ +3.6%,$インディー・セミコンダクタ(INDI.US)$ +2.9%,$ロケット・ラボUSA(RKLB.US)$ +2.4%,$リヴィアン・オートモーティブ(RIVN.US)$ +1.2%
Other news:
• $WeTrade Group(WETG.US)$ +47.8%(announces $50 million sales of monkeypox virus test kits to Par...
コラムTop upgrades and downgrades on 7/18: JPM, GRAB, GM, KHC and more
• $ボルグワーナー(BWA.US)$ : Deutsche Bank Upgrades to Buy from Hold - PT $48 (from $43)
• $エクスペンシファイ(EXFY.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $25 (from $20)
• $グラブ・ホールディングス(GRAB.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $3
• $フーリハン・ローキー(HLI.US)$ : Morgan Stanley Upgrades to Equalweight from Underweight - PT $82 (from $95)
• $JPモルガン・チェース(JPM.US)$ : Berenberg Upgrades to Hold from Sell - PT ...
WATCHLIST 05/17 TUESDAY
- Stock breaking out and moving higher. Looking to add above $13
$エクスペンシファイ(EXFY.US)$
- stock breaking out after it reported earnings recently. Co announced a 50M buyback. Adding above $21.5
$JEクリーンテック・ホールディングズ(JCSE.US)$
- Recent IPO. moving higher after hitting bottom. Stocking having multiple green day recently. Watching next key resistance at $14.50
$H&Rブロック(HRB.US)$
- Stock breaking out on the recent earnings report. Needs to br...
コラムTop upgrades and downgrades on 4/25
• $アドバンスト・マイクロ・デバイス(AMD)(AMD.US)$ : Raymond James Upgrades to Strong Buy from Outperform - PT $160
• $オートネーション(AN.US)$ : Truist Securities Upgrades to Buy from Hold - PT $140 (from $130)
• $バイオライフ・ソリューションズ(BLFS.US)$ : Oppenheimer Upgrades to Outperform from Perform - PT $28
• $バイオマリン・ファーマシューティカル(BMRN.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $113 (from $96)
• $ゴーダディ(GDDY.US)$ : Piper Sandler Upgrades to Overweight ...
コラムToday's pre-market stock movers: CLVS, PATH, DARE and more
• $クロビス・オンコロジー(CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $デア・バイオサイエンス(DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $クーラー・テクノロジー・グループ(KULR.US)$ +9.5% (secured a battery sa...
Good news!
https://www.accountingtoday.com/news/expensify-reports-72-revenue-jump-in-q3
まだコメントはありません